<DOC>
	<DOC>NCT01223898</DOC>
	<brief_summary>This study will evaluate the effects of multiple doses of nilotinib on the pharmacokinetics and metabolism of midazolam (as a sensitive CYP3A probe) in CML patients. The following extension study does evaluate the safety of nilotinib.</brief_summary>
	<brief_title>To Evaluate the Effects of Multiple Doses of Nilotinib on the Pharmacokinetics and Metabolism of Midazolam in CML Patients With Additional Extension Phase to Evaluate the Safety of Nilotinib</brief_title>
	<detailed_description />
	<mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
	<mesh_term>Midazolam</mesh_term>
	<criteria>1. Patients with a cytopathologically confirmed diagnosis of Ph+ CML or Philadelphia chromosome negative (Ph) CML patients in accelerated or chronic phase who are resistant and/or intolerant against at least one prior therapy with a BCRABL tyrosine kinase inhibitor 2. Female or male ≥ 18 years of age 3. Patients who are nilotinib naïve at study entry, e.g. did not receive any nilotinib treatment prior to study 4. WHO Performance Status of ≤ 2 1. Known cytopathologically confirmed CNS infiltration (in absence of suspicion of CNS involvement, lumbar puncture not required). 2. Impaired cardiac function 3. History of acute pancreatitis within 1 year of study entry or past medical history of chronic pancreatitis. 4. Patients actively receiving therapy with the prohibited comedications (CYP3A4 inhibitors or inducers, or CYP2C inducers) 5. Patients who are currently receiving treatment with any medications that have the potential to prolong the QT interval 6. Treatment with immunotherapy or chemotherapy within 3 days (6 weeks for nitrosurea or mitomycinC) prior to Day 1 or who have not recovered from side effects of such therapy. 7. Treatment with imatinib within 1 week prior to Day 1 or who have not recovered from side effects of such therapy. 8. Patients who have hypersensitivity to midazolam or related compounds Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>CML,</keyword>
	<keyword>nilotinib,</keyword>
	<keyword>midazolam</keyword>
</DOC>